Education
About Us
Working with TipRanks
Follow Us
Cellectar Biosciences (CLRB)
NASDAQ:CLRB
Total Valuation
Cellectar Biosciences has a market cap or net worth of $11.70M. The enterprise value is -$3.98M.
Market Cap$11.70M
Enterprise Value-$3.98M
Share Statistics
Cellectar Biosciences has 4,240,129 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding4,240,129
Owned by Insiders1.77%
Owned by Institutions3.75%
Financial Efficiency
Cellectar Biosciences’s return on equity (ROE) is -2.20 and return on invested capital (ROIC) is -222.48%.
Return on Equity (ROE)-2.20
Return on Assets (ROA)-1.45
Return on Invested Capital (ROIC)-222.48%
Return on Capital Employed (ROCE)-2.25
Revenue Per Employee0.00
Profits Per Employee-1.98M
Employee Count11
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Cellectar Biosciences is ―. Cellectar Biosciences’s PEG ratio is 0.00458.
PE Ratio―
PS Ratio0.00
PB Ratio0.78
Price to Fair Value0.78
Price to FCF-0.33
Price to Operating Cash Flow-0.51
PEG Ratio0.00458
Income Statement
In the last 12 months, Cellectar Biosciences had revenue of 0.00 and earned -21.79M in profits. Earnings per share was -8.35.
Revenue0.00
Gross Profit-213.60K
Operating Income-22.98M
Pretax Income-21.79M
Net Income-21.79M
EBITDA-22.77M
Earnings Per Share (EPS)-8.35
Cash Flow
In the last 12 months, operating cash flow was -23.12M and capital expenditures -5.88K, giving a free cash flow of -23.12M billion.
Operating Cash Flow-23.12M
Free Cash Flow-23.12M
Free Cash Flow per Share-5.45
Dividends & Yields
Cellectar Biosciences pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.27
52-Week Price Change-70.79%
50-Day Moving Average3.24
200-Day Moving Average4.82
Relative Strength Index (RSI)39.59
Average Volume (3m)105.19K
Important Dates
Cellectar Biosciences upcoming earnings date is May 12, 2026, TBA (Confirmed).
Last Earnings DateMar 4, 2026
Next Earnings DateMay 12, 2026
Ex-Dividend Date―
Financial Position
Cellectar Biosciences as a current ratio of 2.96, with Debt / Equity ratio of 4.13%
Current Ratio2.96
Quick Ratio2.96
Debt to Market Cap0.01
Net Debt to EBITDA0.56
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Cellectar Biosciences has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Cellectar Biosciences EV to EBITDA ratio is 0.22, with an EV/FCF ratio of 0.22.
EV to Sales0.00
EV to EBITDA0.22
EV to Free Cash Flow0.22
EV to Operating Cash Flow0.22
Balance Sheet
Cellectar Biosciences has $13.20M in cash and marketable securities with $409.59K in debt, giving a net cash position of $12.79M billion.
Cash & Marketable Securities$13.20M
Total Debt$409.59K
Net Cash$12.79M
Net Cash Per Share$3.02
Tangible Book Value Per Share$3.80
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Cellectar Biosciences is $14.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$14.00
Price Target Upside325.53% Upside
Analyst ConsensusModerate Buy
Analyst Count1
Revenue Growth Forecast―
EPS Growth Forecast79.31%